Everything below concerns FSFI endpoint. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-04. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4 melanocortin receptor | Other melanocortin subtypes are also activated |
| Typical route in approved use | Subcutaneous injection | Single-use format in the marketed product |
| Elimination half-life | Roughly two to three hours | Short exposure supports as-needed use |
| Common adverse events | Nausea, flushing, headache | Generally transient but can be dose limiting |
| Main studied group | Premenopausal women with low desire | Controlled data outside this group are limited |
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
have found that NAD+ directly regulates protein-protein interactions. They also show that one of the causes of age-related decline in DNA repair may be increased binding of the protein DBC1 (Deleted in Breast Cancer 1) to PARP1 (poly[ADP–ribose] polymerase 1) as NAD+ levels decline during aging. The decline in cellular concentrations of NAD+ during aging likely contributes to the aging process and to the pathogenesis of the chronic diseases of aging. However, evidence for age-associated NAD+ decline in humans remains inconsistent and may depend on the tissue or biological compartment examined, with recent studies reporting stable whole-blood NAD+ levels across age and lifestyle interventions. Thus, modulation of NAD+ metabolism has been investigated in the context of cancer, radiation response, and aging.
The Japanese government reluctantly acceded to the intervention, as British and American diplomatic intercession was not forthcoming, and Japan was in no position to militarily resist three major European powers simultaneously. The three powers had 38 warships with a displacement of 95,000 tons already deployed in East Asia, whereas the Imperial Japanese Navy had only 31 warships in total with a displacement of 57,000 tons. After futile diplomatic efforts to enlist the support of the United States and Great Britain, on 5 May 1895, Prime Minister Itō Hirobumi announced the withdrawal of Japanese forces from the Liaodong Peninsula in exchange for an additional indemnity of 30 million kuping taels (450 million yen). The last Japanese troops departed in December. Much to Japan's astonishment and consternation, Russia moved almost immediately to occupy the entire Liaodong Peninsula and especially to fortify Port Arthur. Germany secured control over concessions in Shandong Province. France and even Great Britain took advantage of a weakened China to seize the port cities of Guangzhouwan and Weihaiwei, respectively, on various pretexts and to expand their spheres of influence. Japan's government felt it had been cheated of its deserved spoils of war by this intervention. This humiliation at the hands of the European powers helped lead to the Gashin Shōtan (臥薪嘗胆) movement.
According to the Sustainable Development Goals Index 2021, 10.35% of the population of Jammu and Kashmir live below the national poverty line, the third-highest among union territories in the country.
Sources: en.wikipedia.org
According to Jurewicz, the third nidana, vijñana, can be compared to the atman's vijñanamaya kosha in Vedic literature, which is the consciousness of the creator and his subjective manifestations. According to Jurewicz, "in Vedic cosmogony, the act of giving a name and a form marks the final formation of the creator's atman." This may go back to the Vedic birth ceremony in which a father gives a name to his son. In Vedic creation pure consciousness creates the world as name and form (nama-rupa) and then enters it. However, in this process, consciousness also hides from itself, losing sight of its real identity. The Buddhist view of consciousness entering name and form depicts a similar chain of events leading to deeper ignorance and entanglement with the world.
The LLNL chemistry, materials, and life science research focuses on chemical engineering, nuclear chemistry, materials science, and biology and bio-nanotechnology. Physics thrust areas include condensed matter and high-pressure physics, optical science and high energy density physics, medical physics and biophysics, and nuclear, particle and accelerator physics. In the area of energy and environmental science, Livermore's emphasis is on carbon and climate, energy, water and the environment, and the national nuclear waste repository. The LLNL engineering activities include micro- and nanotechnology, lasers and optics, biotechnology, precision engineering, nondestructive characterization, modeling and simulation, systems and decision science, and sensors, imaging and communications. LLNL is a computing organization with capabilities in computer science, software engineering, data science, modeling and simulation, information technology, and cyber security. Lawrence Livermore National Laboratory has worked out several energy technologies in the field of coal gasification, shale oil extraction, geothermal energy, advanced battery research, solar energy, and fusion energy. Main oil shale processing technologies worked out by the Lawrence Livermore National Laboratory are LLNL HRS (hot-recycled-solid), LLNL RISE (in situ extraction technology) and LLNL radiofrequency technologies.
== Rank and classification == There are several classifications in powerlifting determining rank. These typically include Elite, Master, Class I, II, III, IV. The Elite standard is considered to be within the top 1% of competing powerlifters. Several standards exist, including the United States Powerlifting Association classifications (USPA), the IPF/Powerlifting America, USAPL (single-ply) classifications, the APF (multi-ply) classifications, and the Anti-Drug Athletes United (ADAU, raw) classifications. The Master classification should not be confused with the Master age division, which refers to athletes who are at least 40 years old.
“Chemoinformatics and Molecular Simulation”; “Chemistry of Supramolecular Nano- and Biosystems”; “Methods of Analytical Chemistry”; “Physical-Chemical Methods in Chemistry”; “Petrochemistry and Catalysis”. Total number of students taking Bachelor, Specialist and master's degree programs is 472 (as of January, 2016).Departments of the Institute of Chemistry educate postgraduates in the following majors: 02.00.01 – Inorganic Chemistry; 02.00.02 – Analytical Chemistry; 02.00.03 – Organic Chemistry; 02.00.04 – Physical Chemistry; 02.00.08 – Chemistry of Organoelement Compounds. There are two dissertation councils functioning in the Institute of Chemistry for thesis defence in chemical sciences: Д 212.081.03 under the Federal State Autonomous Institution of Higher Education “Kazan (Volga Region) Federal University”; majors allowed for defence: 02.00.01 – Inorganic Chemistry; 02.00.08 – Chemistry of Organoelement Compounds; Chairman of the Council is Professor Vladimir I. Galkin, Doctor of Chemistry;
Sources: en.wikipedia.org
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.
It means the product is taken shortly before anticipated activity instead of every day. This pattern reduces total exposure and shapes how safety monitoring is planned. It also means effects are expected to be temporary rather than cumulative.
Desire is assessed through validated self-report questionnaires, sometimes paired with event counts and a distress scale. These instruments capture subjective experience, so results depend on how participants interpret the questions. No laboratory marker currently substitutes for such reporting.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.